^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zigakibart (FUB523)

    i
    Other names: FUB523, BION-1301, BION 1301, BION1301, FUB 523, FUB-523
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    APRIL inhibitor
    Associations

    News

    Trials
    6ms
    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. (clinicaltrials.gov)
    P3, N=223, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zigakibart (FUB523)
    6ms
    SHIFT: A Study to Assess the Effects of Zigakibart on IgA Nephropathy. (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    zigakibart (FUB523)
    6ms
    BEYOND: A Study of Zigakibart in Adults With IgA Nephropathy (clinicaltrials.gov)
    P3, N=350, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    zigakibart (FUB523)
    11ms
    A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy(The BEYOND Study) (ChiCTR2500096892)
    P3, N=292, Recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P3 trial
    |
    zigakibart (FUB523)
    12ms
    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. (clinicaltrials.gov)
    P3, N=220, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial
    |
    zigakibart (FUB523)